|
Colorectal Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed the plasma levels of HPP1 mfcDNA in mCRC patients treated with a combination therapy containing a fluoropyrimidine, oxaliplatin and bevacizumab to test whether HPP1 mfcDNA is a suitable prognostic and response biomarker.
|
28124380 |
2017 |
|
Colorectal Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Phosphoproteome Characterization of Human Colorectal Cancer SW620 Cell-Derived Exosomes and New Phosphosite Discovery for C-HPP.
|
27470641 |
2016 |
|
Colorectal Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
We were able to provide evidence that methylation of HLTF and especially HPP1 detected in serum is strongly correlated with cell death in CRC using LDH as surrogate marker.
|
24708595 |
2014 |
|
Colorectal Carcinoma
|
0.090 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation status of HLTF and HPP1 was examined in pretherapeutic sera of 311 patients with CRC and matched primary tissues of 54 stage IV patients using methylation-specific quantitative PCR.
|
22362391 |
2012 |
|
Colorectal Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
We have shown earlier that the hypermethylation of the genes HLTF and HPP1/TPEF are independent prognostic serum markers in colorectal cancer identifying patients with increased risk of death.
|
19282772 |
2009 |
|
Colorectal Carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Methylated secreted frizzled-related protein gene 2 (SFRP2), hyperplastic polyposis protein gene (HPP1) and O6-methylguanine-DNA methyltransferase gene (MGMT) in stools from 52 patients with CRC, 35 patients with benign colorectal diseases and 24 normal individuals were analyzed using methylation-specific PCR.
|
17352030 |
2007 |
|
Colorectal Carcinoma
|
0.090 |
PosttranslationalModification
|
disease |
BEFREE |
Using the Methylight assay, TPEF/HPP1 gene methylation was assessed in primary colorectal cancers (n = 47), matched normal colon mucosa, as well as in the liver metastasis of 24 patients with colorectal cancer, and compared to the methylation status of the TIMP-3, APC, DAPK, caveolin-2, and p16 genes.
|
16207479 |
2005 |
|
Colorectal Carcinoma
|
0.090 |
PosttranslationalModification
|
disease |
BEFREE |
It has been shown that HPP1 expression is silenced by HPP1 gene hypermethylation in sporadic colorectal cancers.
|
12460892 |
2002 |
|
Colorectal Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
There was an inverse relationship between methylation level and mRNA expression in cancers (r = -0.67; P < 0.001), and 5-aza-2-deoxycytidine treatment restored HPP1 expression in two colorectal cancer cell lines.
|
11120884 |
2001 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
HPP1 (hyperplastic polyposis protein 1), a tumor suppressor gene, is downregulated by promoter hypermethylation in a number of tumor types including colon cancer. c-Myc is also known to play a role in the suppression of HPP1 expression via binding to a promoter region cognate E-box site.
|
24919179 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Multinomial logistic regression models based on the CGI methylation profiles from normal mucosa correctly identified 78.9% of cancer patients and 87.9% of non-cancer (neoplasia-free+polyp) patients (P=4.93 x 10(-7)) using APC, HPP1, p16, SFRP4, WIF1 and ESR1 methylation as the most informative variables.
|
18542073 |
2008 |
|
Neoplasms
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
Locally advanced tumor categories (pT3/4) showed a higher rate of hypermethylation of HPP1 (90%) than did early tumor categories (pT1/2 categories, 40%; p = 0.0036).
|
16619216 |
2006 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Five (100%) of 5 MSI-H tumors, 2 (50%) of 4 MSI-L tumors, and 8 (35%) of 23 MSS tumors demonstrated HPP1 hypermethylation.
|
12384516 |
2002 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
In situ hybridization of HPP1 indicated that expression occurs in epithelial and stromal elements in normal mucosa but is silenced in both cell types in early colonic neoplasia.
|
11120884 |
2001 |
|
Adenocarcinoma
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
In comparison with adenocarcinomas of the stomach, SB-AC revealed a significantly higher rate of hypermethylation of HPP1 (86% versus 54%, p = 0.0003), p16(INK4A) (32% versus 10%, p = 0.0006), and a significantly lower rate of hypermethylation of APC (48% versus 84%, p = 0.0001).
|
16619216 |
2006 |
|
Adenocarcinoma
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
The methylation of p16 is correlated with smoking history and methylation of HPP1 was significantly more frequent in adenocarcinomas than in squamous cell carcinomas.
|
15201980 |
2004 |
|
Adenocarcinoma
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
We sought then to determine the prevalence of HPP1 silencing by DNA methylation in gastric adenocarcinomas and to define any association of this event with microsatellite instability (MSI) or hMLH1 hypermethylation.
|
12384516 |
2002 |
|
Adenocarcinoma
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
HPP1 methylation was observed in 24 of 48 (50%) adenocarcinomas and in 4 of 10 (40%) dysplasias.
|
12460892 |
2002 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Phosphoproteome Characterization of Human Colorectal Cancer SW620 Cell-Derived Exosomes and New Phosphosite Discovery for C-HPP.
|
27470641 |
2016 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
In this manuscript we describe how the Spanish HPP-16 consortium has developed a B/D platform with five programs focused on selected medical areas: cancer, obesity, cardiovascular, infectious and rheumatic diseases.
|
25686859 |
2015 |
|
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
In this manuscript we describe how the Spanish HPP-16 consortium has developed a B/D platform with five programs focused on selected medical areas: cancer, obesity, cardiovascular, infectious and rheumatic diseases.
|
25686859 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have shown earlier that the hypermethylation of the genes HLTF and HPP1/TPEF are independent prognostic serum markers in colorectal cancer identifying patients with increased risk of death.
|
19282772 |
2009 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Multinomial logistic regression models based on the CGI methylation profiles from normal mucosa correctly identified 78.9% of cancer patients and 87.9% of non-cancer (neoplasia-free+polyp) patients (P=4.93 x 10(-7)) using APC, HPP1, p16, SFRP4, WIF1 and ESR1 methylation as the most informative variables.
|
18542073 |
2008 |
|
Carcinogenesis
|
0.030 |
PosttranslationalModification
|
phenotype |
BEFREE |
Distinct TPEF/HPP1 gene methylation patterns in gastric cancer indicate a field effect in gastric carcinogenesis.
|
18799374 |
2008 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Multinomial logistic regression models based on the CGI methylation profiles from normal mucosa correctly identified 78.9% of cancer patients and 87.9% of non-cancer (neoplasia-free+polyp) patients (P=4.93 x 10(-7)) using APC, HPP1, p16, SFRP4, WIF1 and ESR1 methylation as the most informative variables.
|
18542073 |
2008 |